We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has approved an olanzapine/samidorphan ...

Please provide your email address to receive an email when new articles are posted on . Olanzapine/samidorphan combination treatment reduced weight gain across several subgroups of individuals at ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders — ...

The FDA approved the antipsychotic combination of olanzapine plus samidorphan (Lybalvi) for adults with schizophrenia or bipolar I disorder, drugmaker Alkermes announced on Tuesday. In schizophrenia, ...

schizophrenia Researchers report on the 52-week extension of the ENLIGHTEN-2 study that assessed the long-term safety and efficacy of treatment schizophrenia with olanzapine and samidorphan. Dual ...

ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet. The Food and Drug ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ...

In a poster presentation at the 73rd Annual Scientific Convention of the Society of Biological Psychiatry meeting in New York, New York, May 10 to 12, researchers reported about an adjunctive ...

— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment — In this global, ...